scispace - formally typeset
Open AccessJournal ArticleDOI

Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys

TLDR
It is demonstrated that it is possible to generate protective immune responses by vaccination with genetically diverse isolates of HIV-1 and suggested that a multicomponent vaccine encoding Env proteins from multiple clades of HIV -1 can generate broad Env-specific T-lymphocyte and antibody responses without antigenic interference.
Abstract
The development of a human immunodeficiency virus type 1 (HIV-1) vaccine that elicits potent cellular and humoral immune responses recognizing divergent strains of HIV-1 will be critical for combating the global AIDS epidemic. The present studies were initiated to examine the magnitude and breadth of envelope (Env)-specific T-lymphocyte and antibody responses generated by vaccines containing either a single or multiple genetically distant HIV-1 Env immunogens. Rhesus monkeys were immunized with DNA prime-recombinant adenovirus boost vaccines encoding a Gag-Pol-Nef polyprotein in combination with either a single Env or a mixture of clade-A, clade-B, and clade-C Envs. Monkeys receiving the multiclade Env immunization developed robust immune responses to all vaccine antigens and, importantly, a greater breadth of Env recognition than monkeys immunized with vaccines including a single Env immunogen. All groups of vaccinated monkeys demonstrated equivalent immune protection following challenge with the pathogenic simian-human immunodeficiency virus 89.6P. These data suggest that a multicomponent vaccine encoding Env proteins from multiple clades of HIV-1 can generate broad Env-specific T-lymphocyte and antibody responses without antigenic interference. This study demonstrates that it is possible to generate protective immune responses by vaccination with genetically diverse isolates of HIV-1.

read more

Citations
More filters
Journal ArticleDOI

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

TL;DR: It was found that coverage of viral diversity using mosaics was greatly increased compared to coverage by natural-sequence vaccine candidates, for both variable and conserved proteins; for conserved HIV-1 proteins, global coverage may be feasible.
Journal ArticleDOI

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys.

TL;DR: Although these monkeys demonstrated a reduction in viremia restricted to the early phase of SIV infection, they showed a prolonged survival that could be predicted by the magnitude of the vaccine-induced cellular immune response, which should guide the evaluation of AIDS vaccines in humans.
Journal ArticleDOI

Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications

TL;DR: A review of the genetic diversity of HIV-1 can be found in this article, with particular emphasis on its pathogenetic and therapeutic implications, as well as the potential for vaccine development.
Journal ArticleDOI

Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates

TL;DR: In animals vaccinated with HIV Gag protein/Montanide and CpG ODN or the TLR7/8 agonist, the presence and type of TLR adjuvant used during primary immunization conferred stability and dramatically influenced the magnitude and quality of the Th1 and CD8+ T cell responses after the rAD-Gag boost.
References
More filters
Journal ArticleDOI

Diversity considerations in HIV-1 vaccine selection.

TL;DR: Consensus or ancestor sequences could be used in vaccine design to minimize the genetic differences between vaccine strains and contemporary isolates, effectively reducing the extent of diversity by half.
Journal ArticleDOI

Challenges and opportunities for development of an AIDS vaccine

TL;DR: The biomedical community is looking towards vaccines to help solve this compelling problem of considerable expense and logistical difficulty in providing antiviral drugs to populations infected with the human immunodeficiency virus throughout the world.
Journal ArticleDOI

Prospects for vaccine protection against HIV-1 infection and AIDS.

TL;DR: Evidence suggesting that cellular immune responses elicited by novel vaccine modalities may attenuate clinical disease caused by HIV-1 is discussed.
Journal ArticleDOI

Modifications of the Human Immunodeficiency Virus Envelope Glycoprotein Enhance Immunogenicity for Genetic Immunization

TL;DR: A modified Env, gp140ΔCFI, stimulated the antibody response to native gp160 while it retained its ability to induce a CTL response, a desirable feature for an AIDS vaccine.
Related Papers (5)